605 related articles for article (PubMed ID: 26494973)
1. Managements of recurrent hepatocellular carcinoma after liver transplantation: A systematic review.
de'Angelis N; Landi F; Carra MC; Azoulay D
World J Gastroenterol; 2015 Oct; 21(39):11185-98. PubMed ID: 26494973
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
Sotiropoulos GC; Nowak KW; Fouzas I; Vernadakis S; Kykalos S; Klein CG; Paul A
Transplant Proc; 2012 Nov; 44(9):2754-6. PubMed ID: 23146514
[TBL] [Abstract][Full Text] [Related]
3. Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.
Wan X; Zhai X; Yan Z; Yang P; Li J; Wu D; Wang K; Xia Y; Shen F
Oncotarget; 2016 Dec; 7(50):83806-83816. PubMed ID: 27566566
[TBL] [Abstract][Full Text] [Related]
4. Clinical analysis of patients with hepatocellular carcinoma recurrence after living-donor liver transplantation.
Na GH; Hong TH; You YK; Kim DG
World J Gastroenterol; 2016 Jul; 22(25):5790-9. PubMed ID: 27433092
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.
Sposito C; Mariani L; Germini A; Flores Reyes M; Bongini M; Grossi G; Bhoori S; Mazzaferro V
J Hepatol; 2013 Jul; 59(1):59-66. PubMed ID: 23500153
[TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation.
Waghray A; Balci B; El-Gazzaz G; Kim R; Pelley R; Narayanan Menon KV; Estfan B; Romero-Marrero C; Aucejo F
Clin Transplant; 2013; 27(4):555-61. PubMed ID: 23758296
[TBL] [Abstract][Full Text] [Related]
7. Comparison of treatment outcome between living donor liver transplantation and sorafenib for patients with hepatocellular carcinoma beyond the Milan criteria.
Cho Y; Lee JH; Lee DH; Cho EJ; Yu SJ; Yi NJ; Lee KW; Kim YJ; Yoon JH; Suh KS
Oncotarget; 2017 Jul; 8(29):47555-47564. PubMed ID: 28548930
[TBL] [Abstract][Full Text] [Related]
8. Adjuvant sorafenib for hepatocellular carcinoma after resection or ablation (STORM): a phase 3, randomised, double-blind, placebo-controlled trial.
Bruix J; Takayama T; Mazzaferro V; Chau GY; Yang J; Kudo M; Cai J; Poon RT; Han KH; Tak WY; Lee HC; Song T; Roayaie S; Bolondi L; Lee KS; Makuuchi M; Souza F; Berre MA; Meinhardt G; Llovet JM;
Lancet Oncol; 2015 Oct; 16(13):1344-54. PubMed ID: 26361969
[TBL] [Abstract][Full Text] [Related]
9. Impact of neo-adjuvant Sorafenib treatment on liver transplantation in HCC patients - a prospective, randomized, double-blind, phase III trial.
Hoffmann K; Ganten T; Gotthardtp D; Radeleff B; Settmacher U; Kollmar O; Nadalin S; Karapanagiotou-Schenkel I; von Kalle C; Jäger D; Büchler MW; Schemmer P
BMC Cancer; 2015 May; 15():392. PubMed ID: 25957784
[TBL] [Abstract][Full Text] [Related]
10. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
[TBL] [Abstract][Full Text] [Related]
11. Role of Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation.
de'Angelis N; Landi F; Nencioni M; Palen A; Lahat E; Salloum C; Compagnon P; Lim C; Costentin C; Calderaro J; Luciani A; Feray C; Azoulay D
Prog Transplant; 2016 Dec; 26(4):348-355. PubMed ID: 27555074
[TBL] [Abstract][Full Text] [Related]
12. Radioembolisation with yttrium‒90 microspheres versus sorafenib for treatment of advanced hepatocellular carcinoma (SARAH): study protocol for a randomised controlled trial.
Vilgrain V; Abdel-Rehim M; Sibert A; Ronot M; Lebtahi R; Castéra L; Chatellier G;
Trials; 2014 Dec; 15():474. PubMed ID: 25472660
[TBL] [Abstract][Full Text] [Related]
13. Sorafenib use in the transplant setting.
Castelli G; Burra P; Giacomin A; Vitale A; Senzolo M; Cillo U; Farinati F
Liver Transpl; 2014 Sep; 20(9):1021-8. PubMed ID: 24809799
[TBL] [Abstract][Full Text] [Related]
14. Liver Transplantation After Neoadjuvant Sorafenib Therapy: Preliminary Experience and Literature Review.
Golse N; Radenne S; Rode A; Ducerf C; Mabrut JY; Merle P
Exp Clin Transplant; 2018 Apr; 16(2):227-236. PubMed ID: 27212671
[TBL] [Abstract][Full Text] [Related]
15. Adjuvant sorafenib after heptectomy for Barcelona Clinic Liver Cancer-stage C hepatocellular carcinoma patients.
Xia F; Wu LL; Lau WY; Huan HB; Wen XD; Ma KS; Li XW; Bie P
World J Gastroenterol; 2016 Jun; 22(23):5384-92. PubMed ID: 27340354
[TBL] [Abstract][Full Text] [Related]
16. Feasibility and safety of sorafenib treatment in hepatocellular carcinoma patients with spontaneous rupture.
Zheng SZ; Liu DJ; Sun P; Yu GS; Xu YT; Gong W; Liu J
World J Gastroenterol; 2014 Nov; 20(43):16275-81. PubMed ID: 25473183
[TBL] [Abstract][Full Text] [Related]
17. Sorafenib after resection improves the outcome of BCLC stage C hepatocellular carcinoma.
Li J; Hou Y; Cai XB; Liu B
World J Gastroenterol; 2016 Apr; 22(15):4034-40. PubMed ID: 27099447
[TBL] [Abstract][Full Text] [Related]
18. Practical Considerations of Real Life of Hepatocellular Carcinoma in a Tertiary Center of Brazil.
Almeida-Carvalho SR; Gomes-Ferraz ML; Loureiro-Matos CA; Benedito-Silva AT; Carvalho-Filho RJ; Renato-Perez R; Miziara-Gonzalez A; Salzedas-Netto AA; Szejnfeld D; D'Ippolito G; Pereira-Lanzoni V; Souza-Silva I
Ann Hepatol; 2017; 16(2):255-262. PubMed ID: 28233747
[TBL] [Abstract][Full Text] [Related]
19. Can sorafenib increase survival for recurrent hepatocellular carcinoma after liver transplantation? A pilot study.
Alsina AE; Makris A; Nenos V; Sucre E; Arrobas J; Franco E; Kemmer N
Am Surg; 2014 Jul; 80(7):680-4. PubMed ID: 24987900
[TBL] [Abstract][Full Text] [Related]
20. Clinical outcomes of patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective study of routine clinical practice in multi-institutions.
Lee SH; Song IH; Noh R; Kang HY; Kim SB; Ko SY; Lee ES; Kim SH; Lee BS; Kim AN; Chae HB; Kim HS; Lee TH; Kang YW; Lee JD; Lee HY
BMC Cancer; 2015 Apr; 15():236. PubMed ID: 25885683
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]